Phipps P A, Moore A R, Gowland G, Khanam A, Willoughby D A
Department of Experimental Pathology, William Harvey Research Institute, London, UK.
Int J Immunopharmacol. 1997 Sep-Oct;19(9-10):569-72. doi: 10.1016/s0192-0561(97)00053-2.
OM-89 is a glycoprotein-rich extract of Escherichia coli shown to be effective in the treatment of rheumatoid arthritis (RA). It has been reported that oral dosing of animals results in the appearance of specific OM-89 antibodies. In the current study we have investigated some of the immunoglobulin isotypes that may be involved. OM-89 antibodies of IgG1, IgG2a and IgM isotypes were measured by ELISA in serum from rats dosed three times a week for 3 weeks at 4 or 40 mg kg(-1). The results showed a small but significant rise in IgM and a greater rise in IgG2a. The possibility that antigens within OM-89 (e.g. hsp65) may have homology with antigens involved in RA raises the possibility that OM-89 antibodies, particularly of the IgG2 class, may block pathogenic antigens from being recognized by T cells.
OM - 89是一种富含糖蛋白的大肠杆菌提取物，已证明其对类风湿性关节炎（RA）的治疗有效。据报道，给动物口服会导致出现特异性OM - 89抗体。在当前研究中，我们调查了可能涉及的一些免疫球蛋白同种型。通过酶联免疫吸附测定（ELISA）法，对每周给药3次、连续3周、剂量为4或40 mg/kg(-1)的大鼠血清中IgG1、IgG2a和IgM同种型的OM - 89抗体进行了检测。结果显示，IgM有小幅但显著的升高，IgG2a升高幅度更大。OM - 89内的抗原（如热休克蛋白65）可能与RA相关抗原具有同源性，这增加了一种可能性，即OM - 89抗体，特别是IgG2类抗体，可能会阻止致病性抗原被T细胞识别。
